SCHEMBL6768634

SCHEMBL6768634

COc1ccc(-c2ccc(S(=O)(=O)NC3CC(CSc4ccccc4)OC3=O)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
ALDH1A1 P00352 4/20 0.41
NAAA Q02083 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MMP2 P08253 8/20 0.41
MMP9 P14780 2/20 0.41
KCNA5 P22460 1/20 0.40
MMP1 P03956 6/20 0.38
MMP3 P08254 6/20 0.38
MMP13 P45452 6/20 0.38
POLB P06746 1/20 0.38
PTGDR Q13258 1/20 0.38
MMP7 P09237 3/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6772860 0.91 MMP2 (0.39) CA12CA9ALDH1A1HPGDMMP2
SCHEMBL6768648 0.87 KCNA5 (0.43) CA12CA1CA2CA9ALDH1A1
SCHEMBL6771966 0.83 ALDH1A1 (0.44) CA12CA1CA2CA9ALDH1A1
SCHEMBL6771937 0.82 ALDH1A1 (0.46) ALDH1A1LMNAHPGDSMN1; SMN2POLB
SCHEMBL6772307 0.82 ALDH1A1 (0.39) CA12CA1CA2CA9ALDH1A1
SCHEMBL6773324 0.80 HSD11B1 (0.39) CA12CA1CA2CA9ALDH1A1
SCHEMBL8752437 0.62 PGR (0.78) ALDH1A1LMNASMN1; SMN2MAPTKMT2A
SCHEMBL18780384 0.61 MAPT (0.46) CA1CA2ALDH1A1LMNAHPGD
SCHEMBL2372012 0.61 KDM4E (0.61) CA1CA2ALDH1A1NAAALMNA
SCHEMBL1722712 0.61 MMP2 (0.61) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6762198-B2 SUCH AS 2-((4'-METHOXY-(1,1'-BIPHENYL)-4-YL)-SULFONYL)-AMINO-3-(2-PHENOXYMETHYL -(1,3)DIOXAN-2-YL)PROPIONIC ACID THE PROCTER & GAMBLE COMPANY 2004-07-13 US disclosed
US-20030225074-A1 Dihetero-substituted metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2003-12-04 US disclosed
US-6566381-B1 For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease THE PROCTER & GAMBLE COMPANY 2003-05-20 US disclosed
EP-1165530-A2 DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-01-02 EP disclosed
WO-2000051993-A2 DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225074-A1 Dihetero-substituted metalloprotease inhibitors ADAM9, ADAM17, ADAM8 CA12 1368/4885CA1 611/4885CA2 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.